Similar articles for PMID: 29791008

Year	Number of Results
1886	1
1893	1
1990	1
1991	1
1994	1
1995	1
1997	2
1998	6
1999	2
2000	2
2001	6
2002	11
2003	12
2004	10
2005	8
2006	3
2007	2
2008	3
2009	4
2010	5
2011	6
2012	2
2013	4
2015	1
2016	1
2017	1
2018	4
2019	2
2020	2
2021	1
2022	1
2024	0

1

The Pharmacology, Pharmacokinetics, Efficacy, and Adverse Events Associated With Kava.

White CM. White CM. J Clin Pharmacol. 2018 Nov;58(11):1396-1405. doi: 10.1002/jcph.1263. Epub 2018 May 23. J Clin Pharmacol. 2018. PMID: 29791008 Review.

2

[Kava-kava preparations--alternative anxiolytics].

Nowakowska E, Ostrowicz A, Chodera A. Nowakowska E, et al. Pol Merkur Lekarski. 1998 Mar;4(21):179-180a. Pol Merkur Lekarski. 1998. PMID: 9640076 Review. Polish.

3

[Kava, kavapyrones and toxic liver injury].

Teschke R. Teschke R. Z Gastroenterol. 2003 May;41(5):395-404. doi: 10.1055/s-2003-39333. Z Gastroenterol. 2003. PMID: 12772052 Review. German.

4

Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro.

Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P, So J, Burka LT. Mathews JM, et al. Drug Metab Dispos. 2005 Oct;33(10):1555-63. doi: 10.1124/dmd.105.004317. Epub 2005 Jul 20. Drug Metab Dispos. 2005. PMID: 16033948

5

A systematic review of the safety of kava extract in the treatment of anxiety.

Stevinson C, Huntley A, Ernst E. Stevinson C, et al. Drug Saf. 2002;25(4):251-61. doi: 10.2165/00002018-200225040-00003. Drug Saf. 2002. PMID: 11994028

6

Kava extract for treating anxiety.

Pittler MH, Edzard E. Pittler MH, et al. Cochrane Database Syst Rev. 2001;(4):CD003383. doi: 10.1002/14651858.CD003383. Cochrane Database Syst Rev. 2001. PMID: 11687196 Updated. Review.

7

Efficacy of kava extract for treating anxiety: systematic review and meta-analysis.

Pittler MH, Ernst E. Pittler MH, et al. J Clin Psychopharmacol. 2000 Feb;20(1):84-9. doi: 10.1097/00004714-200002000-00014. J Clin Psychopharmacol. 2000. PMID: 10653213

8

Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop.

Thomsen M, Schmidt M. Thomsen M, et al. J Ethnopharmacol. 2021 Mar 25;268:113582. doi: 10.1016/j.jep.2020.113582. Epub 2020 Nov 12. J Ethnopharmacol. 2021. PMID: 33189846 Review.

9

Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?

Sarris J, Teschke R, Stough C, Scholey A, Schweitzer I. Sarris J, et al. Planta Med. 2011 Jan;77(2):107-10. doi: 10.1055/s-0030-1250290. Epub 2010 Sep 2. Planta Med. 2011. PMID: 20814850

10

Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism.

Chua HC, Christensen ET, Hoestgaard-Jensen K, Hartiadi LY, Ramzan I, Jensen AA, Absalom NL, Chebib M. Chua HC, et al. PLoS One. 2016 Jun 22;11(6):e0157700. doi: 10.1371/journal.pone.0157700. eCollection 2016. PLoS One. 2016. PMID: 27332705 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year